Evidence map›Paper›PMID 29306668›Full record

Observational studyAlzheimer's & dementia : the journal of the Alzheimer's Association2018

A prognostic model of Alzheimer's disease relying on multiple longitudinal measures and time-to-event data.

Kan Li, Richard O'Brien, Michael Lutz, Sheng Luo, Alzheimer's Disease Neuroimaging Initiative

Abstract readObservational Study
In one paragraph

Observational study in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change.Movement disorders : official journal of the Movement Disorder Society · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kan LiDepartment of Biostatistics, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Richard O'BrienDepartment of Neurology, Duke University School of Medicine, Durham, NC, USA.
Michael LutzDepartment of Neurology, Duke University School of Medicine, Durham, NC, USA.
Sheng LuoDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA. Electronic address: sheng.luo@duke.edu.
Alzheimer's Disease Neuroimaging Initiative

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MICHAEL W WEINER · 2016 to 2026
$226.7M
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Parkinson's Disease Clinical Trial: Statistical CenterU01NS043127 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LUO, SHENG · 2001 to 2015
$8.0M
Statistical Methods for Clinical Trials with Multivariate Longitudinal OutcomesR01NS091307 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LUO, SHENG · 2015 to 2018
$1.2M
NIA NIH HHS U01 AG024904NIA NIH HHS U19 AG024904NINDS NIH HHS R01 NS091307NINDS NIH HHS U01 NS043127
6 · The paper itself

Abstract

introductionCharacterizing progression in Alzheimer's disease is critically important for early detection and targeted treatment. The objective was to develop a prognostic model, based on multivariate longitudinal markers, for predicting progression-free survival in patients with mild cognitive impairment.

methodsThe information contained in multiple longitudinal markers was extracted using multivariate functional principal components analysis and used as predictors in the Cox regression models. Cross-validation was used for selecting the best model based on Alzheimer's Disease Neuroimaging Initiative-1. External validation was conducted on Alzheimer's Disease Neuroimaging Initiative-2.

resultsModel comparison yielded a prognostic index computed as the weighted combination of historical information of five neurocognitive longitudinal markers that are routinely collected in observational studies. The comprehensive validity analysis provided solid evidence of the usefulness of the model for predicting Alzheimer's disease progression. DISCUSSION: The prognostic model was improved by incorporating multiple longitudinal markers. It is useful for monitoring disease and identifying patients for clinical trial recruitment.

Indexed as

BiomarkersDisease ProgressionAgedAlzheimer DiseaseBrainCognitive DysfunctionEarly DiagnosisFemaleHumansLongitudinal StudiesMaleModels, StatisticalNeuroimagingNeuropsychological TestsPrognosisBiomarkersADNIExternal validationMild cognitive impairmentMultivariate functional component analysisPrediction

Identifiers

PMID29306668
PMCPMC5938096

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.